Market closedNon-fractional

Larimar Therapeutics/LRMR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Larimar Therapeutics

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Ticker

LRMR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Bala Cynwyd, United States

Employees

42

LRMR Metrics

BasicAdvanced
$487M
Market cap
-
P/E ratio
-$0.97
EPS
0.77
Beta
-
Dividend rate
$487M
0.77
17.986
17.701
1.958
2.315
-17.32%
-26.75%
2.1
2.1
-9.686
-5.00%
-33.67%

What the Analysts think about LRMR

Analyst Ratings

Majority rating from 6 analysts.
Buy

LRMR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$15M
13.18%
Profit margin
0.00%
NaN%

LRMR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 14.89%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.19
-$0.21
-$0.30
-$0.27
-
Expected
-$0.20
-$0.22
-$0.25
-$0.24
-$0.31
Surprise
-2.56%
-6.00%
21.26%
14.89%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Larimar Therapeutics stock?

Larimar Therapeutics (LRMR) has a market cap of $487M as of July 05, 2024.

What is the P/E ratio for Larimar Therapeutics stock?

The price to earnings (P/E) ratio for Larimar Therapeutics (LRMR) stock is 0 as of July 05, 2024.

Does Larimar Therapeutics stock pay dividends?

No, Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Larimar Therapeutics dividend payment date?

Larimar Therapeutics (LRMR) stock does not pay dividends to its shareholders.

What is the beta indicator for Larimar Therapeutics?

Larimar Therapeutics (LRMR) has a beta rating of 0.77. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Larimar Therapeutics stock

Buy or sell Larimar Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing